G-protein-coupled receptors (GPCRs) recognize ligands of widely different efficacies, from inverse to partial and full agonists, which transduce cellular signals at differentiated levels. However, the mechanism of such graded activation remains unclear. Using the Gaussian accelerated molecular dynamics (GaMD) method that enables both unconstrained enhanced sampling and free energy calculation, we have performed extensive GaMD simulations (∼19 μs in total) to investigate structural dynamics of the M 2 muscarinic GPCR that is bound by the full agonist iperoxo (IXO), the partial agonist arecoline (ARC), and the inverse agonist 3-quinuclidinyl-benzilate (QNB), in the presence or absence of the G-protein mimetic nanobody. In the receptornanobody complex, IXO binding leads to higher fluctuations in the protein-coupling interface than ARC, especially in the receptor transmembrane helix 5 (TM5), TM6, and TM7 intracellular domains that are essential elements for GPCR activation, but less flexibility in the receptor extracellular region due to stronger binding compared with ARC. Two different binding poses are revealed for ARC in the orthosteric pocket. Removal of the nanobody leads to GPCR deactivation that is characterized by inward movement of the TM6 intracellular end. Distinct low-energy intermediate conformational states are identified for the IXO-and ARC-bound M 2 receptor. Both dissociation and binding of an orthosteric ligand are observed in a single all-atom GPCR simulation in the case of partial agonist ARC binding to the M 2 receptor. This study demonstrates the applicability of GaMD for exploring free energy landscapes of large biomolecules and the simulations provide important insights into the GPCR functional mechanism. cellular signaling | ligand recognition | protein-protein interactions | allostery | drug discovery G -protein-coupled receptors (GPCRs) are primary targets of about one-third of currently marketed drugs. They recognize ligands of widely different efficacies, from inverse to partial and full agonists, which transduce cellular signals at differentiated levels. Increasing experimental and computational evidence suggests that GPCRs exist in an ensemble of different conformations that interconvert dynamically during activation and ligand recognition (1-3). The structure, dynamics, and function of GPCRs result from underlying free energy landscapes (4). However, quantitative characterization of the GPCR activation and ligand-dependent free energy profiles has proved challenging (4-12).
G
-protein-coupled receptors (GPCRs) are primary targets of about one-third of currently marketed drugs. They recognize ligands of widely different efficacies, from inverse to partial and full agonists, which transduce cellular signals at differentiated levels. Increasing experimental and computational evidence suggests that GPCRs exist in an ensemble of different conformations that interconvert dynamically during activation and ligand recognition (1) (2) (3) . The structure, dynamics, and function of GPCRs result from underlying free energy landscapes (4) . However, quantitative characterization of the GPCR activation and ligand-dependent free energy profiles has proved challenging (4) (5) (6) (7) (8) (9) (10) (11) (12) .
The M 2 muscarinic GPCR is widely distributed in mammalian tissues. It plays a key role in regulating the human heart rate and heart contraction forces. The M 2 receptor has been crystallized in both an inactive state bound by the inverse agonist 3-quinuclidinylbenzilate (QNB) (13) and an active state bound by the full agonist iperoxo (IXO) and a G-protein mimetic nanobody (14) . The receptor activation is characterized by rearrangements of the transmembrane (TM) helices 5, 6 , and 7, particularly closing of the ligand-binding pocket, outward tilting of the TM6 cytoplasmic end, and close interaction of Tyr206 5.58 and Tyr440 7.53 in the G-proteincoupling site (14) . The residue superscripts denote the Ballesteros-Weinstein (BW) numbering of GPCRs (15) .
In addition to binding inverse and full agonists, the M 2 receptor recognizes partial agonists that often possess lower affinities and elicit submaximal activity (16) . Coupling of the receptor with the G protein or mimetic nanobody typically increases agonist binding affinities (17) . However, structural information of partial agonist binding is scarce, except for few other GPCRs (18) . How can one GPCR accommodate chemically diverse ligands? What are the structural signatures underlying the binding of different ligands? Why do some partial agonists exhibit lower binding affinities than full agonists? Is it easier for partial agonists to dissociate from the receptor? What are the pathways of ligand dissociation and binding? Because the partial agonists elicit only submaximal activity of GPCRs, do they stabilize different receptor conformations? It is important to address these questions to elucidate the GPCR functional mechanism.
Using Gaussian accelerated molecular dynamics (GaMD) simulations that enable both unconstrained enhanced sampling and free energy calculation (19) , here we investigate structural dynamics of the M 2 receptor that is bound by the full agonist IXO, the partial agonist arecoline (ARC), and the inverse agonist QNB, in the presence or absence of the G-protein mimetic nanobody Nb9-8 (Table S1) . Upon binding of different ligands, the receptor exhibits distinct flexibility and free energy profiles in the orthosteric pocket, the extracellular vestibule, and the intracellular G-protein-coupling site, for which the sizes are characterized by the perimeter of triangle formed by the C α atoms of Tyr104 3.33
−Tyr403
6.51 −Tyr426 7.39 or "tyrosine lid" (14) , the distance between the C α atoms of Tyr177 in extracellular loop 2 (ECL2) and Asn410 6.58 , and the C α atom distance between Arg121 3.50 and Thr386 6.34 , respectively. The receptor orthosteric pocket samples distinct closed and open conformations, and the G-protein-coupling site interconverts between the inactive, intermediate, and fully active states. We have observed both dissociation and binding of an orthosteric ligand in a GPCR all-atom simulation. Therefore, we are able to obtain a detailed picture of GPCR graded activation.
Significance G-protein-coupled receptors (GPCRs) represent primary targets of about one-third of currently marketed drugs. The structure, dynamics, and function of GPCRs result from complex free energy landscapes. In this work, we have applied Gaussian accelerated molecular dynamics (GaMD) to study the ligand-dependent behavior of the M 2 muscarinic GPCR. Extensive GaMD simulations have revealed distinct structural flexibility and free energy profiles that depict graded activation of the M 2 receptor. We have captured both dissociation and binding of an orthosteric ligand in a single allatom GPCR simulation. GaMD is well poised to study large biomolecules and ligand recognition for drug discovery.
Results
Agonist-Dependent Flexibility and Free Energy Profiles of the Nanobody-Coupled Receptor. In the presence of the G-protein mimetic nanobody, the M 2 receptor exhibits varied structural flexibility when the ligand is changed from full agonist IXO to partial agonist ARC (Fig. 1A) . Binding of ARC leads to significantly increased fluctuations in the ECL2 and orthosteric pocket. This is consistent with the fact that ARC possesses lower affinity than IXO (14, 16, 20) . Thus, weaker interaction is formed between ARC and the receptor. Surprisingly, opposite flexibility change was observed in the receptor intracellular half. Binding of IXO leads to higher fluctuations in the G-protein-coupling interface, especially in the TM5, TM6, and TM7 intracellular domains, which have been shown as essential elements for activation of GPCRs (1). Therefore, increased flexibility of the receptor intracellular domains upon full agonist binding apparently contributes to GPCR activation.
Potential of mean force (PMF) calculations showed that the IXO-nanobody-bound M 2 receptor is confined in a local energy well centered at (14.5 Å, 13.5 Å) in the C α atom distances between Arg121 3.50
−Thr386
6.34 and Tyr177 ECL2 −Asn410 6.58 (Fig. 1B and  Fig. S1 ). The receptor maintains the active X-ray conformation through GaMD simulations. The distance between the ligandcharged N atom and the C γ atom of Asp103 3.32 adopts a free energy minimum at 4.5 Å (same as the X-ray conformation) (Fig.  1C) . The tyrosine lid exhibits an energy minimum at 30 Å, being similar to 29.7 Å in the closed X-ray conformation (Fig. 1C) .
In comparison, the ARC-nanobody-bound M 2 receptor exhibits a narrower energy well in the Arg121 3 .50
6.34 distance than the IXO-nanobody-bound form (Fig. 1D ). This result is consistent with the above finding that changing the ligand from IXO to ARC leads to reduced flexibility in the receptor intracellular domains. On the other hand, the tyrosine lid explores a larger conformational space with weaker binding of ARC (Fig. 1E) . ARC samples two low-energy conformations, "ARC-P1" (Fig. 1F ) and "ARC-P1′" (Fig. 1G) , for which the preferred distances between ARC and Asp103 3.32 are 3.5 Å and 5.5 Å, respectively (Fig. S2) . The ARC-P1′ pose is closely similar to that obtained from Glide docking. ARC forms weaker interaction with the M 2 receptor than IXO and exhibits dynamic binding.
Ligand-Dependent Dynamics of the Nanobody-Free Receptor. Removal of the G-protein mimetic nanobody leads to deactivation of the M 2 receptor even with agonist binding. This is reflected by decreased distances between Arg121 3.50 and Thr386 6.34 in GaMD simulations of the M 2 -ARC and M 2 -IXO complexes (Figs. S3 and S4). The receptor in these two complexes is more flexible than in the QNB-bound form (Fig. 2 A-C and Fig. S5 ). The IXO-bound receptor exhibits lower flexibility in the extracellular vestibule, but higher fluctuations in the TM5, TM6, and TM7 intracellular domains than the ARC-bound form (Fig. S6) , being similar to the nanobody-bound complexes (Fig. S7) . Moreover, ARC undergoes significantly higher fluctuations than IXO ( Fig. 2 B and C) .
In the QNB-bound receptor, the Tyr177 ECL2 −Asn410 6.58 distance exhibits a free energy minimum at 14.5 Å, similar to 15.9 Å in the X-ray structure (13) . Binding of the smaller agonists ARC and IXO shrinks the extracellular vestibule to an energy minimum distance of 12.5 Å between Tyr177 ECL2 and Asn410 6.58 , although with fluctuations ( Fig. 2 E and F) . On the intracellular side, the global energy minimum is identified for the nanobody-free receptor in the inactive state with ∼6-7 Å distance between Arg121 Upon binding QNB, the receptor tyrosine lid is confined to the X-ray conformation (Fig. 2G ). QNB remains tightly bound to the orthosteric site through the GaMD simulations. In contrast, the full and partial agonists allow the receptor to sample a significantly larger conformational space in the tyrosine lid ( Fig. 2 H and I) . IXO is able to escape out of the orthosteric pocket in one of the GaMD simulations, visiting the extracellular vestibule with 12.5 Å distance between ligand and Asp103 3.32 ( Fig. 2I and Fig. S8 ). In the case of ARC, not only does it escape out of the orthosteric pocket, but also it dissociates completely and rebinds repeatedly to the . ARC is shown in thick sticks, the receptor in orange ribbons, and the interacting protein residues in thin sticks. The docking conformation of ARC in the 4MQS crystal structure is also shown in red for comparison.
receptor (described in more detail below). The distance between ARC and Asp103 3.32 samples different low-energy states at 3.5 Å (ARC-P1), 5.5 Å (ARC-P1′), and ∼10 Å (ARC-P2) (Fig. 2H ). This finding presumably results from weaker binding of ARC compared with IXO and QNB (14, 16, 20) . (Fig. 3A) , for which the tyrosine lid samples free energy minima at ∼30 Å and ∼33 Å, respectively (Fig. 3C ). In the presence of the G-protein mimetic nanobody, IXO shifts the receptor conformational equilibrium to the closed state. In contrast, ARC allows the orthosteric pocket to sample both the closed and open states. The G-protein-coupling site samples the inactive, intermediates I1 and I2, and active conformational states (Fig. 3B) , for which lowenergy minima are found for the Arg121 3.50
6.34 distance at 6.0-7.0 Å, ∼10 Å, ∼12 Å, and ∼15 Å, respectively (Fig. 3D) . QNB confines the receptor in the inactive state, whereas binding of IXO and ARC, along with the nanobody, shifts the receptor to the fully active state. In contrast, the full/partial agonist alone allows the receptor to sample more than one low-energy state. The (Table S1 ), ARC was observed to dissociate completely and rebind to the receptor multiple times as indicated by the time course of the ligandAsp103 3.32 distance (Fig. 4A and Movie S1). Four dissociation (denoted "D1," "D2," "D3," and "D4") and three binding (denoted "B1," "B2," and "B3") events took place. ARC exited the receptor via three extracellular openings, one formed between ECL2 and ECL3 (D1, Fig. 4B ), the second between ECL2 and TM2 and TM7 (D2, Fig. 4F ), and the third between ECL2 and TM7 (D3 and D4, Fig. 4 G and H) . ARC rebound to the receptor through two of the three openings, i.e., ECL2/ECL3 (B1, Fig. 4C ) and ECL2/TM7 (B2 and B3, Fig. 4 E and G) .
To obtain a quantitative picture of the ligand-binding pathways, the density-based spatial clustering of applications with noise (DBSCAN) algorithm (21) was applied to cluster trajectory snapshots of the ligand by combining all 10 GaMD simulations of M 2 -ARC (total 9,100 ns). Energetic reweighting (19, 22) was then performed on each of the ligand clusters to recover the original free energy (details in SI Methods). Ten ligand clusters with the lowest free energies are shown in Fig. 4I . A global energy minimum (0 kcal/mol) is found for cluster "C1" in the orthosteric pocket. The second-lowest energy is identified for cluster "C2" (1.34 kcal/mol) at the center of the extracellular vestibule between ECL2 and TM7. Two clusters of higher energies, "C3" with 2.01 kcal/mol and "C4" with 2.29 kcal/mol, appear to connect C1 in the orthosteric pocket and C2 in the extracellular vestibule. A cavity formed by the extracellular domains of TM3/TM2/TM7 is filled with two clusters, "C5" (2.33 kcal/mol) and "C8" (2.69 kcal/mol). Similarly, another cavity formed by the TM4/TM5/TM6 extracellular domains is filled with clusters "C7" and "C9" with 2.49 kcal/mol and 3.15 kcal/mol free energies, respectively. In the extracellular vestibule, although ARC was observed to exit between ECL2 and TM2 and TM7 in one of the dissociation events, this location does not appear among the 10 lowest-energy clusters. In contrast, two energetically favored clusters are found in the opening between ECL2 and ECL3, i.e., "C6" (2.36 kcal/mol) and "C10" (3.22 kcal/mol). Therefore, clusters C1 ↔ C3 ↔ C4 ↔ C2 ↔ C10 ↔ C6 appear to represent an energetically preferred pathway for ARC dissociation and binding. IXO also follows a similar pathway during dissociation from the orthosteric site to the ECL2/ECL3 opening and rebinding to the center of the extracellular vestibule ( Fig. S8 and Movie S2).
Discussion
In this study, detailed ligand-dependent dynamics and free energy profiles of the M 2 muscarinic GPCR have been obtained through extensive GaMD simulations (∼19 us in total). The energy minimum states identified from GaMD simulations of the QNB-bound and the IXO-nanobody-bound receptor are the same as the inactive and fully active receptor X-ray structures (13, 14) , respectively. The simulations also revealed new low-energy states in the IXO/ARC-bound receptor upon removal the nanobody. Whereas the inverse agonist QNB with high binding affinity (∼0.06 nM) (14) remains tightly bound to the orthosteric site, the full and partial agonists with lower affinities, ∼5 μM for ARC (16, 20) and ∼0.01 μM for IXO (14) , exhibit significantly higher fluctuations. We have captured both dissociation and binding of an orthosteric ligand in a single all-atom GPCR simulation in the case of ARC binding to the M 2 receptor. These results are consistent with the recent experimental finding that the G-protein mimetic nanobody stabilizes a closed receptor conformation and dramatically affects the association and dissociation of GPCR ligands (17) . Notably, Dror et al. (23) successfully observed both binding and dissociation of allosteric modulators at the M 2 receptor through long-timescale conventional MD (cMD) simulations. However, the allosteric site is located in the receptor extracellular vestibule, ∼15Å above the deeply buried orthosteric site. It is also important to note that a direct link between the binding affinity of individual GPCR ligands and their efficacy is still lacking (16, 20, 24) . Whereas ARC exhibits lower affinity than IXO or QNB as investigated in the present study, certain partial agonists are not necessarily weaker binders compared with full or inverse agonists (16, 24) . Nevertheless, there appears to be a correlation between efficacy and the breadth of the dispersion of affinities for agonists of the M 2 receptor (16, 20, 25) . The GaMD simulations provided important insights into the binding mechanism of three studied ligands and GPCR graded activation.
Overall, the M 2 receptor samples a large conformational space (Fig. 5) . In the presence of the G-protein mimetic nanobody, the receptor is stabilized in the fully active state with the most open intracellular pocket and the narrowest extracellular vestibule. In the orthosteric pocket, IXO stabilizes the receptor in the closed state, whereas ARC binding allows the receptor to change between the closed and open states with two alternative poses (ARC-P1 and ARC-P1′). Such dynamic binding of the partial agonist, along with multiple associated receptor conformations, has previously been observed in NMR experiments of the peroxisome proliferatoractivated receptor γ (26). Removal of the nanobody leads to deactivation of the M 2 receptor with inward displacement of the TM6 cytoplasmic end. This is consistent with extensive experimental and computational studies of GPCRs, especially on the β 2 -adrenergic receptor (β 2 AR) (6) , respectively. Note that our earlier accelerated MD (aMD) simulations captured a similar conformational change during activation of the apo M 2 receptor that exhibits basal activity (12) . Even without agonist binding, the apo receptor undergoes transient outward movement of the TM6 cytoplasmic end up to ∼12 Å. To a certain extent, the intermediate I2 in the present study can be considered an "active-like" state, which has been used to define the agonist-bound adenosine A 2A receptor (A 2A AR) (27) . In summary, graded activation of the M 2 receptor is characterized by outward movement of the TM6 cytoplasmic end at increasing magnitudes when the ligand changes from inverse to partial and full agonists.
The orthosteric pocket samples two distinct conformations, being open in the QNB-bound M 2 receptor (13) and closed in the IXO-nanobody-bound form (14) . It interconverts dynamically between the closed and open states when the ligand is changed from IXO to ARC in the nanobody-coupled receptor (Fig. 3C) , although the extracellular vestibule remains to adopt the narrowest opening (Fig. S9B) . It also exhibits a broad energy well covering both the closed and open states in the M 2 -IXO and M 2 -ARC complexes. Given such plasticity, the orthosteric pocket of the M 2 receptor is able to accommodate different ligands of various sizes (14, 16) . In addition, the extracellular vestibule in the IXO-and ARC-bound receptor samples both the narrow and wide opening conformations, for which the distances between Tyr177 ECL2 and Asn410 6.58 are 12.5 Å and ∼16 Å, respectively( Fig. 2 and Fig. S9) . Overall, the extracellular vestibule appears highly flexible. Binding of allosteric modulators may stabilize it in specific conformations and alter the orthosteric ligand-mediated responses (14, 23) .
In earlier computational studies, ligand-dependent dynamics of GPCRs were investigated using the cMD (7, 10) , metadynamics (8, 9) , and aMD (11) methods. Whereas cMD simulations revealed distinct conformational changes in several known GPCR activation elements (7), these simulations lasting several hundred nanoseconds were not long enough to capture the entire GPCR activation/ deactivation processes. For the β 2 AR, cMD simulations were combined with coarse-grained modeling to sample the receptor ensemble conformations (10) . Moreover, metadynamics were used to characterize free energy landscapes of the β 2 AR (8) and A 2A AR (9) . However, metadynamics require predefined collective variables and may constrain the dynamic GPCR activation or deactivation pathways. Recently, we applied aMD to simulate binding of different ligands to the M 3 muscarinic receptor (11) . Although the aMD simulations successfully captured binding of the partial and full agonists without constraints, the boost potential suffered from large energetic noise and precluded accurate reweighting to recover the original free energy landscapes. By constructing boost potential that follows a Gaussian distribution, GaMD enabled simultaneous unconstrained enhanced sampling and free energy calculations. It allows for detailed characterization of the liganddependent dynamics of the M 2 receptor.
During one of the GaMD simulations, IXO with ∼0.01 μM affinity escapes out of the orthosteric pocket and visits the extracellular vestibule (Fig. S8 and Movie S2). For ARC with 5.0 μM binding affinity, not only does it escape out of the orthosteric pocket, but also it dissociates completely and rebinds to the receptor repeatedly during a 2,030-ns GaMD simulation (Fig. 4 and Movie S1). A pathway connecting the orthosteric site, the center of the extracellular vestibule, and the ECL2/ECL3 opening appears to be energetically favorable for ligand dissociation and binding (Fig. 4I) . This route has also been identified as the dominant pathway for drug binding to the β 2 AR (28). Therefore, it may be a common pathway adopted by class A GPCRs for ligand recognition, although this may also depend on structural arrangement of the receptor extracellular domains and ligand size and chemical properties. For the M 2 receptor, it is worth investigating the binding of more ligands and associated receptor dynamics in the future, e.g., the N-methylscopolamine and atropine inverse agonists (16) , the pilocarpine and McN-A343 partial agonists that elicit more consistent partial response of the M 2 receptor (16, 20) , etc. In this context, although ligand dissociation from β 2 AR was simulated in a previous random acceleration MD (RAMD) study (29) , it was difficult to capture rebinding of the ligand. The ligand was observed to exit with similar probability via the ECL2/ECL3 and ECL2/TM2/TM7 openings, but the RAMD simulations could not differentiate the two pathways energetically. Another steered MD study on ligand dissociation from the β-ARs also suggested the two routes "may serve indistinguishably for ligand entry and exit" (ref. 30, p. 6) . Although free energy profiles were obtained from the steered MD simulations, the ligand was constrained to predetermined CAVER channels, which may not reflect the real pathways as observed in cMD simulations (28) . In comparison, GaMD provides unconstrained enhanced sampling and allows for free ligand diffusion. The simulation-derived free energy profiles can be used to characterize the ligand pathways quantitatively. Notably, the orthosteric pocket and extracellular vestibule were calculated as two low-energy binding sites of ARC. This finding is consistent with previous binding assay experiments, suggesting that several partial agonists have two or more binding sites in the M 2 receptor (16, 31) . Earlier computational studies also identified the extracellular vestibule as a metastable site during binding of orthosteric ligands to the M 2 and M 3 muscarinic receptors (5, 11) . Therefore, GaMD is well suited for investigating ligand binding and dissociation of GPCRs and other large biomolecules. With continuing computing advances and method development, sufficient sampling of biomolecular conformations and ligand pathways may become increasingly useful for drug discovery.
Methods
GaMD simulations were performed on the M 2 muscarinic receptor that is bound by the full agonist IXO, the partial agonist ARC, and the inverse agonist QNB, in the presence or absence of the G-protein mimetic nanobody Nb9-8. For each of the receptor complexes, initial energy minimization, thermalization, and 100-ns cMD equilibration were performed using NAMD2.10 (32). Using the NAMD output structure, along with the system topology and CHARMM36 (33) force-field files, ParmEd was used to convert the simulation files into the AMBER format (34) . The GaMD module implemented in the graphics processing unit (GPU) version of AMBER14 (19, 34) was then applied to perform GaMD simulation, which included 10-ns short cMD simulation used to collect potential statistics for calculating the GaMD acceleration parameters, 50-ns equilibration after adding the boost potential, and finally multiple independent GaMD production runs with randomized initial atomic velocities. The simulation frames were saved every 0.1 ps for analysis. The GaMD production simulations performed on the different M 2 receptor systems at 400-ns to 2,030-ns lengths (total ∼19 μs) are listed in Table S1 . Details of the GaMD simulations, energetic reweighting, system setup, and simulation analysis are provided in SI Methods.
